ABBV - AbbVie Inc.
191.635
-0.525 -0.274%
Share volume: 156,664
Last Updated: Wed 05 Feb 2025 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.19%
PREVIOUS CLOSE
CHG
CHG%
$192.16
-0.53
-0.27%
Fundamental analysis
54%
Profitability
33%
Dept financing
32%
Liquidity
11%
Performance
92%
Performance
5 Days
3.29%
1 Month
5.47%
3 Months
-5.82%
6 Months
3.03%
1 Year
10.91%
2 Year
30.98%
Key data
Stock price
$191.64
DAY RANGE
$189.59 - $193.34
52 WEEK RANGE
$153.58 - $207.32
52 WEEK CHANGE
$8.54
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news